Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 20;10(4):869.
doi: 10.3390/jcm10040869.

Immunological Risk Factors in Recurrent Pregnancy Loss: Guidelines Versus Current State of the Art

Kilian Vomstein  1 , Katharina Feil  1 , Laura Strobel  1 , Anna Aulitzky  1 , Susanne Hofer-Tollinger  1 , Ruben-Jeremias Kuon  2 , Bettina Toth  1
Affiliations
Review

Immunological Risk Factors in Recurrent Pregnancy Loss: Guidelines Versus Current State of the Art

Kilian Vomstein et al. J Clin Med. .

Abstract

Around 1-5% of all couples experience recurrent pregnancy loss (RPL). Established risk factors include anatomical, genetic, endocrine, and hemostatic alterations. With around 50% of idiopathic cases, immunological risk factors are getting into the scientific focus, however international guidelines hardly take them into account. Within this review, the current state of immunological risk factors in RPL in international guidelines of the European Society of Reproduction and Embryology (ESHRE), American Society of Reproductive Medicine (ASRM), German/Austrian/Swiss Society of Obstetrics and Gynecology (DGGG/OEGGG/SGGG) and the Royal College of Obstetricians and Gynecologists (RCOG) are evaluated. Special attention was drawn to recommendations in the guidelines regarding diagnostic factors such as autoantibodies, natural killer cells, regulatory T cells, dendritic cells, plasma cells, and human leukocyte antigen system (HLA)-sharing as well as treatment options such as corticosteroids, intralipids, intravenous immunoglobulins, aspirin and heparin in RPL. Finally, the current state of the art focusing on both diagnostic and therapeutic options was summarized.

Keywords: NK cells; recurrent miscarriage; regulatory T cells; reproductive immunology.

PubMed Disclaimer

Conflict of interest statement

B.T. and R.J.K. are shareholders of Reprognostics GbR, all other authors declare no conflict of interest.

References

    1. WHO Recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Acta Obs. Gynecol. Scand. 1977;56:247–253. - PubMed
    1. Practice Committee of the American Society for Reproductive Medicine Definitions of infertility and recurrent pregnancy loss. Fertil. Steril. 2008;90:S60. doi: 10.1016/j.fertnstert.2008.08.065. - DOI - PubMed
    1. Rai R., Regan L. Recurrent miscarriage. Lancet. 2006;368:601–611. doi: 10.1016/S0140-6736(06)69204-0. - DOI - PubMed
    1. Eshre Guideline Group on RPL. Bender Atik R., Christiansen O.B., Elson J., Kolte A.M., Lewis S., Middeldorp S., Nelen W., Peramo B., Quenby S., et al. Eshre guideline: Recurrent pregnancy loss. Hum. Reprod. Open. 2018;2018:hoy004. - PMC - PubMed
    1. Practice Committee of the American Society for Reproductive Medicine Evaluation and treatment of recurrent pregnancy loss: A committee opinion. Fertil. Steril. 2012;98:1103–1111. doi: 10.1016/j.fertnstert.2012.06.048. - DOI - PubMed

LinkOut - more resources